Meta-Analysis
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2021; 13(10): 585-592
Published online Oct 26, 2021. doi: 10.4330/wjc.v13.i10.585
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
Dimitrios Ioannis Patoulias, Aristi Boulmpou, Eleftherios Teperikidis, Alexandra Katsimardou, Fotios Siskos, Michael Doumas, Christodoulos E Papadopoulos, Vassilios Vassilikos
Dimitrios Ioannis Patoulias, Alexandra Katsimardou, Fotios Siskos, Michael Doumas, Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki 54642, Greece
Aristi Boulmpou, Eleftherios Teperikidis, Christodoulos E Papadopoulos, Vassilios Vassilikos, Third Department of Cardiology, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki 54642, Greece
Author contributions: Patoulias DI and Doumas M conceived and designed the study; Patoulias DI, Boulmpou A and Teperikidis E collected and analyzed data; Patoulias DI, Boulmpou A and Siskos F performed study quality and risk of bias assessment; Patoulias DI, Boulnpou A, Katsimardou A and Papadopoulos CE wrote the first draft of the study; Doumas M and Vassilikos V critically revised the final draft.
Conflict-of-interest statement: The authors declare no conflict of interest.
PRISMA 2009 Checklist statement: The present meta-analysis was conducted according to 2009 PRISMA Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dimitrios Ioannis Patoulias, MD, MSc, Doctor, Research Fellow, Research Scientist, Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Konstantinoupoleos 49 Str., Thessaloniki 54642, Greece. dipatoulias@gmail.com
Received: March 29, 2021
Peer-review started: March 29, 2021
First decision: June 25, 2021
Revised: July 8, 2021
Accepted: September 10, 2021
Article in press: September 10, 2021
Published online: October 26, 2021
Processing time: 205 Days and 14.3 Hours
Core Tip

Core Tip: The antidiabetic efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors has already been proven in recently published large randomized controlled trials. The purpose of the present meta-analysis was to clarify the impact of antidiabetic therapy with DPP-4 inhibitors on surrogate cardiovascular outcomes, and to elucidate the effect of these drugs on major cardiac arrhythmias. According to our analysis, this drug class does not significantly affect the risk for any of the addressed cardiovascular outcomes; however, it increases the risk for atrial flutter compared to placebo.